Nurix Therapeutics(NASDAQ) NRIX

Nurix Therapeutics makes medicines that help the body destroy harmful proteins. These treatments aim to help people with cancer or inflammatory diseases. The company uses advanced technology to discover these potential drugs.

A Look at the Pipeline

• Bexobrutideg (NX-5948): Oral medicine designed to destroy a specific signaling protein to treat blood cancers; currently in a Phase 3 study comparing it to existing treatments.
• NX-1607: Pill that blocks a protein to activate the immune system against tumors; currently being tested in patients with lung, colon, and prostate cancers.
• Discovery Platform: System that uses artificial intelligence and automated chemistry to find new ways to target proteins; helps create first-in-class drug candidates.
• Collaborative Pipeline: Research programs managed with large pharmaceutical partners like Gilead and Sanofi; focuses on finding new treatments for cancer and autoimmune conditions.

Recent Deals and Clinical Progress

• Partnered with Roche in June 2026 to develop and manufacture bexobrutideg for patients worldwide.
• Extended a research agreement with Gilead in Aug. 2026 to continue working on a specific drug target.
• Enrolled the first patient in a randomized Phase 3 trial for blood cancer in Aug. 2026.
• Decided to stop clinical development of the drug zelebrudomide in Aug. 2026 to focus on other oncology projects.

How Nurix Targets Disease

Nurix uses its proprietary platform to create drugs that can reach proteins previously considered untreatable by standard medicines. The company has raised $1.2 billion through partnerships, allowing it to fund several clinical trials at the same time.

The Financial Scorecard

• License revenue was $653.2 million for the nine months ended Aug. 31, 2026, up from $30.0 million for the same period in 2025.
• Net income was $373.1 million for the nine months ended Aug. 31, 2026, compared to a net loss of $186.2 million for the same period in 2025.
• Research and development expenses increased by $17.2 million for the nine months ended Aug. 31, 2026.
• Cash, cash equivalents, and marketable securities were $1.1 billion as of Aug. 31, 2026.

Bottom Line

Nurix has grown from an early-stage researcher into a clinical-stage company with multiple drug candidates and major global partnerships. This evolution has provided the capital necessary to advance its most promising treatments toward potential regulatory approval.